Codexis (CDXS) Tops Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Codexis Reports Financial Results for the Third Quarter of 2015
November 4, 2015 4:06 PM ESTRecords net income of $5.4 million on revenues of $17.4 million
Recognizes licensing agreement milestone payments totaling $11.5 million from GSK and Merck
Affirms 2015 revenue guidance and raises gross margin guidance
Conference call begins at 4:30 p.m. Eastern time today
REDWOOD CITY, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2015, and provides an update on the company's business progress.
"We are reporting strong financial and... More



